NT-proBNP and stem cell factor plasma concentrations are independently associated with cardiovascular outcomes in end-stage renal disease hemodialysis patients.

Fiche publication

Date publication

novembre 2022

Journal

European heart journal open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEVIGNES Marie-Dominique , Pr ROSSIGNOL Patrick

Tous les auteurs :
Rossignol P, Duarte K, Bresso E, A Å, Devignes MD, Eriksson N, Girerd N, Glerup R, Jardine AG, Holdaas H, Lamiral Z, Leroy C, Massy Z, März W, Krämer B, Wu PH, Schmieder R, Soveri I, Christensen JH, Svensson M, Zannad F, Fellström B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36600882

Résumé

End-stage renal disease (ESRD) treated by chronic hemodialysis (HD) is associated with poor cardiovascular (CV) outcomes, with no available evidence-based therapeutics. A multiplexed proteomic approach may identify new pathophysiological pathways associated with CV outcomes, potentially actionable for precision medicine.